These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Pacini F; Castagna MG; Brilli L; Pentheroudakis G; Ann Oncol; 2012 Oct; 23 Suppl 7():vii110-9. PubMed ID: 22997443 [No Abstract] [Full Text] [Related]
3. New therapeutic advances in the management of progressive thyroid cancer. Woyach JA; Shah MH Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279 [TBL] [Abstract][Full Text] [Related]
4. New directions in the systemic treatment of metastatic thyroid cancer. Higgins MJ; Forastiere A; Marur S Oncology (Williston Park); 2009 Aug; 23(9):768-75. PubMed ID: 19777762 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in the treatment of thyroid carcinoma. Wells SA CA Cancer J Clin; 1996; 46(5):258-60. PubMed ID: 8806392 [No Abstract] [Full Text] [Related]
6. Management of microcarcinomas (papillary and medullary) of the thyroid. Wu LS; Milan SA Curr Opin Oncol; 2013 Jan; 25(1):27-32. PubMed ID: 23042124 [TBL] [Abstract][Full Text] [Related]
7. Contemporary management of papillary carcinoma of the thyroid gland. Rosenbaum MA; McHenry CR Expert Rev Anticancer Ther; 2009 Mar; 9(3):317-29. PubMed ID: 19275510 [TBL] [Abstract][Full Text] [Related]
8. Treatments sought for intractable forms of thyroid cancer. Ziegler J J Natl Cancer Inst; 1997 Dec; 89(23):1752-4. PubMed ID: 9392613 [No Abstract] [Full Text] [Related]
9. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. San Román Gil M; Pozas J; Molina-Cerrillo J; Gómez J; Pian H; Pozas M; Carrato A; Grande E; Alonso-Gordoa T Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668761 [TBL] [Abstract][Full Text] [Related]
10. [Therapy in thyroid cancer]. Esik O Orv Hetil; 2003 Nov; 144(46):2287-8. PubMed ID: 14702925 [No Abstract] [Full Text] [Related]
11. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442 [TBL] [Abstract][Full Text] [Related]
12. Detection of medullary carcinoma of the thyroid with I-131 MIBG. Thomas CC; Cowan RJ; Albertson DA; Cooper MR Clin Nucl Med; 1994 Dec; 19(12):1066-8. PubMed ID: 7874804 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous manifestations of thyroid cancer: a report of four cases and review of the literature. Alwaheeb S; Ghazarian D; Boerner SL; Asa SL J Clin Pathol; 2004 Apr; 57(4):435-8. PubMed ID: 15047753 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of a thyroid neoplasm infiltrating the respiratory-digestive tracts]. Betkowski A; Pogorzelski A; Cyran-Rymarz A Otolaryngol Pol; 2001; 55(1):99-102. PubMed ID: 11355488 [TBL] [Abstract][Full Text] [Related]
16. New Horizons: Emerging Therapies and Targets in Thyroid Cancer. Ringel MD J Clin Endocrinol Metab; 2021 Jan; 106(1):e382-e388. PubMed ID: 32977343 [TBL] [Abstract][Full Text] [Related]
17. Management of invasive and advanced thyroid cancer. Favia G; Iacobone M; Zanella S; Ciarleglio FA Minerva Endocrinol; 2009 Mar; 34(1):37-55. PubMed ID: 19209127 [TBL] [Abstract][Full Text] [Related]
18. Cerebellar metastasis as first metastasis from papillary thyroid carcinoma. Pazaitou-Panayiotou K; Kaprara A; Chrisoulidou A; Boudina M; Georgiou E; Patakiouta F; Drimonitis A; Vainas I Endocr J; 2005 Dec; 52(6):653-7. PubMed ID: 16410655 [TBL] [Abstract][Full Text] [Related]
19. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Messina M; Robinson BG Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):290-301. PubMed ID: 17315037 [TBL] [Abstract][Full Text] [Related]